Randomised controlled trial
Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial
- Randomised controlled trial
- placebo-controlled
28 patients (12.7%) discontinued treatment (15 on atorvastatin, 13 on placebo)
Authors' conclusion
Among patients with bicuspid aortic valve without severe valvular dysfunction, atorvastatin treatment was not effective in reducing the progression of ascending aorta dilation and aortic valve calcification during 3 years of treatment despite a significant reduction in low-density lipoprotein cholesterol levels.
Study context
- Population
- Adults with bicuspid aortic valve, nonsevere valvular dysfunction and calcification, ascending aorta diameter ≤50 mm192 completed 36 months
- Participants
- 220 adults
- Comparison
- Atorvastatin vs placebo
- Primary endpoint
- Growth of maximum ascending aorta diameter
- Follow-up
- 3 years
Primary result
As reported in the abstract
Increase in maximum ascending aorta diameter
P = 0.613
Further findings
Median, mg/dL
| Outcome | Atorvastatin | Placebo | P value |
|---|---|---|---|
| Change in LDL-C | −30 (IQR −51.65 to −1.75 mg/dL) | 6 (IQR −4, 22.5 mg/dL) | P < 0.001 |
Progression of aortic valve calcium score
- No significant difference between groups
- P = 0.167
Valvular dysfunction
- No significant difference between groups
Original publication
Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial. Circulation. Published 28 May 2024. doi:10.1161/circulationaha.123.067537
Summarised from the published abstract; every number is checked against it